Lunai Bioworks (LNAI) Q3 2025 earnings summary

Executive summary

• Renovaro Inc. operates through two subsidiaries: Renovaro Biosciences (cell/gene therapies for cancer and infectious diseases) and Renovaro Cube (AI-driven early cancer detection). Focus has shifted to AI diagnostics post-acquisition of GEDi Cube.

• The company is pre-revenue and pre-clinical, with no product sales to date. It relies on external funding for operations and R&D.

• Net income for the quarter ended March 31, 2025, was $189,176, a significant improvement from a net loss of $58.99 million in the same quarter last year, mainly due to lower impairment charges and favorable fair value adjustments.

• A major acquisition of GEDi Cube (now Renovaro Cube) was completed in February 2024, and a subsequent acquisition of Biosymetrics closed in April 2025.

Financial highlights

• Net income for Q1 2025 was $189,176, compared to a net loss of $58.99 million in Q1 2024.

• Net loss for the nine months ended March 31, 2025, was $51.28 million, down from $72.69 million year-over-year.

• Operating expenses for Q1 2025 were $4.16 million, down 92% from $51.38 million in Q1 2024, mainly due to a $42.6 million decrease in intangible asset impairment.

• Cash at March 31, 2025, was $923,002, up from $220,467 at June 30, 2024.

• Total assets declined to $117.7 million from $163.1 million at June 30, 2024, primarily due to goodwill impairment.

Outlook and guidance

• Management has streamlined operations to focus on AI-driven cancer diagnostics and is seeking additional funding through equity or debt.

• There is substantial doubt about the company's ability to continue as a going concern without new financing.

• Any new funding will be used for working capital, product commercialization, and clinical/regulatory development.